NCT06742892View on ClinicalTrials.gov

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

June 5, 2027

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

HLX43 DOSE 1

Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 2

Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 3

Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Hunan

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY